Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
NCT03930641
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Age Related Macular Degeneration
Interventions
DRUG:
RTH258
Sponsor
Novartis Pharmaceuticals